Data from Menoufia University Advance Knowledge in Hepatitis C Virus [Sofosbuvir (+) Daclatasvir (+) Ribavirin In Egyptian Patients With Hepatitis C Virus: Therapeutic Outcomes and the Prognostic Role of Natural Killer Cells].

A study conducted by researchers at Menoufia University in Shibin Al Kawm, Egypt, explored the therapeutic outcomes of Sofosbuvir (+) Daclatasvir (+) Ribavirin (SOF+DCV+RBV) therapy in Egyptian patients with Hepatitis C Virus (HCV). The study focused on the impact of this therapy on natural killer (NK) cells, which are a subset of immune cells. The researchers found that NK cell activation and cytotoxicity increased during HCV antiviral therapy and were associated with better treatment outcomes. This research provides valuable insights into the role of NK cells in HCV treatment and highlights the importance of establishing an inhibitory cytotoxic NK profile for successful therapy. [Extracted from the article]